Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...

It promises the benefits of a 10,000-step walk in just 30 minutes. No gym membership required. Just a pair of shoes and a ...

A new result shows that just about anyone at risk for Alzheimer’s – and that’s most of us – can change the trajectory of ...

The study included 2,469 participants from France, Japan and Finland who ... Study co-author Jenni Lehtisalo, a research fellow at the Finnish Institute for Health and Welfare, said the main takeaway ...

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study. In the high-dose cohort from the ongoing Phase Ib/IIa Brainshuttle AD ...

K-Bio showcases AI and protein removal advancements for dementia at Toronto conference Innovations in dementia treatment using AI and advanced drug delivery systems are at the forefront of discussions ...

Virtual reality looks to be a useful tool on multiple fronts to help prevent falls among older residents, including those in ...

Dementia in Asia-Pacific is expected to triple by the end of the decade. In Asia's fast ageing populations, including ...

ZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer's type in adults. As a new generation of ...

A ground-breaking study gives those with elevated Alzheimer’s risk a new path for changing the trajectory of their brain health. The researchers reported a significant improvement in global cognition ...

South Korean pharmaceutical and biotech companies are presenting their latest Alzheimer’s research at the world’s largest ...

Regina Barber and Rachel Carlson of Short Wave talk about endangered eagles in Japan, the lifestyles of deep-living ocean ...